title: Expression of functional lung resistance--related protein predicts poor outcome in adult T-cell leukemia.
abstract: Chemotherapy of patients with adult T-cell leukemia (ATL) has been unsuccessful. The poor outcome is thought to be caused mainly by the drug resistance of ATL cells. Lung resistance-related protein (LRP) is a novel protein associated with drug resistance. The expression of LRP messenger RNA (mRNA) was evaluated by slot blot analysis in 55 patients with ATL. Of these patients, 36 had acute, 12 chronic, and 7 lymphoma-type ATL. The expression levels of LRP mRNA were significantly higher in chronic ATL than in lymphoma-type ATL (P =.007). The expression of LRP mRNA was higher in patients with white blood cell counts above 30,000/microL (P =.038) or with abnormal lymphocyte counts above 10,000/microL (P =.007) than in the remaining patients. The enhanced efflux of [(14)C]doxorubicin from nuclei isolated from ATL cells that expressed high levels of LRP was inhibited by a polyclonal antibody against LRP, and the accumulation of doxorubicin in the isolated nuclei was increased by the anti-LRP antibody. In acute and lymphoma-type ATL patients, high expression of LRP mRNA at diagnosis correlated with shorter survival, and a Cox proportional hazards model showed that LRP expression is an independent prognostic factor. These findings suggest that functionally active LRP is expressed in some ATL cells and that it is involved in drug resistance and poor prognosis in ATL. (Blood. 2001;98:1160-1165)
authors.affiliation: Department of Cancer Chemotherapy, Institute for Cancer Research; the Second Department of Internal Medicine; and the Department of Public Health, Faculty of Medicine, Kagoshima University, Kagoshima, Japan.
authors.forename: N
authors.initials: N
authors.lastname: Ohno
authors.forename: A
authors.initials: A
authors.lastname: Tani
authors.forename: K
authors.initials: K
authors.lastname: Uozumi
authors.forename: S
authors.initials: S
authors.lastname: Hanada
authors.forename: T
authors.initials: T
authors.lastname: Furukawa
authors.forename: S
authors.initials: S
authors.lastname: Akiba
authors.forename: T
authors.initials: T
authors.lastname: Sumizawa
authors.forename: A
authors.initials: A
authors.lastname: Utsunomiya
authors.forename: T
authors.initials: T
authors.lastname: Arima
authors.forename: S
authors.initials: S
authors.lastname: Akiyama
mesh_terms: D021581:Active Transport, Cell Nucleus / Q000187:drug effects; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002250:Carbon Radioisotopes; D004317:Doxorubicin / Q000493:pharmacokinetics; D018432:Drug Resistance, Multiple; D005260:Female; D006801:Humans; D066298:In Vitro Techniques; D015461:Leukemia, Prolymphocytic, T-Cell / Q000175:diagnosis / Q000378:metabolism; D015459:Leukemia-Lymphoma, Adult T-Cell / Q000175:diagnosis* / Q000378:metabolism; D008198:Lymph Nodes / Q000378:metabolism / Q000473:pathology; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000235:genetics* / Q000494:pharmacology; D017063:Outcome Assessment, Health Care; D011379:Prognosis; D016016:Proportional Hazards Models; D012333:RNA, Messenger / Q000097:blood / Q000378:metabolism; D015996:Survival Rate; D014407:Tumor Cells, Cultured; D020394:Vault Ribonucleoprotein Particles / Q000235:genetics*; D000099187:Major Vault Protein
chemical_list: D002250:Carbon Radioisotopes; D004317:Doxorubicin; D009363:Neoplasm Proteins; D012333:RNA, Messenger; D020394:Vault Ribonucleoprotein Particles; D000099187:Major Vault Protein